Uprima

Withdrawn

This medicine's authorisation has been withdrawn

apomorphine

Overview

The marketing authorisation for Uprima has not been renewed by the marketing authorisation holder and is now withdrawn.

Product information

29/05/2006

This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.

 

Product information documents contain:

• summary of product characteristics (annex I);
• manufacturing authorisation holder responsible for batch release (annex IIA);
• conditions of the marketing authorisation (annex IIB);
• labelling (annex IIIA);
• package leaflet (annex IIIB).

Product details

• Name of medicine:
  Uprima
• Active substance:
  apomorphine hydrochloride
• International non-proprietary name (INN) or common name:
  apomorphine
• Therapeutic area (MeSH):
  Erectile Dysfunction
• Anatomical therapeutic chemical (ATC) code:
  G04BE

Pharmacotherapeutic group

Urologicals

Therapeutic indication

Treatment of men with erectile dysfunction, which is the inability to achieve or maintain a penile erection sufficient for satisfactory sexual performance.
In order for Uprima to be effective, sexual stimulation is required.

Authorisation details

• EMA product number:
  EMEA/H/C/000327
• Marketing authorisation holder:
  Abbott Laboratories Ltd.

  Queenborough; Kent ME11 5EL; United Kingdom

• Marketing authorisation issued:
  28/05/2001
• Revision:
  4